PNV 0.43% $2.35 polynovo limited

PNV v ARX, page-64

  1. bar
    698 Posts.
    lightbulb Created with Sketch. 110
    Agree. The demand will be in areas that need improved outcomes. i am thinking tendon repair where blood supply is limited. Think of the tendo Achilles a major foot ankle tendon. for a footballer it could be the end of a career. Surgeons will use our products to strengthen tendon repairs and get better outcomes. DW has mentioned rotator cuff repair which is a huge area. Breast reconstruction is again a major area. Females with the BRCA gene mutation for breast are now having elective mastectomies and reconstruction at the same time. This is where our products can help a good cause. Hernias are not that lucrative and as pointed out there are cheap options in the market.
 
watchlist Created with Sketch. Add PNV (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.